Universität zu Köln

Journal Article

Glaser, M., Von Levetzow, C., Michels, S., Nogova, L., Katzenmeier, M., Wompner, C., Schmitz, J., Bitter, E., Terjung, I., Passmann, E., Schaufler, D., Eisert, A. K., Fischer, R. N., Riedel, R., Weber, J-P., Hahne, S., Merkelbach-Bruse, S., Buttner, R., Wolf, J. and Scheffler, M. (2022). The biological effect of small-scale ROS1 aberrations: An in silico analysis. Ann. Oncol., 33 (7). S. S1327 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041

Glaser, M., von Levetzow, C., Michels, S., Nogova, L., Katzenmeier, M., Woempner, C., Schmitz, J., Bitter, E., Terjung, I., Passmann, E., Schaufler, D., Eisert, A., Fischer, R., Riedel, R., Weber, J-P., Hahne, S., Merkelbach-Bruse, S., Buettner, R., Wolf, J. and Scheffler, M. (2022). ROS1 aberrations in non-small cell lung cancer patients without rearrangements: Clinical and molecular characteristics. Ann. Oncol., 33. S. S56 - 2. AMSTERDAM: ELSEVIER. ISSN 1569-8041

Glaser, M., von Levetzow, C., Michels, S., Nogova, L., Katzenmeier, M., Woempner, C., Schmitz, J., Bitter, E., Terjung, I., Passmann, E., Schaufler, D., Eisert, A., Fischer, R. N., Riedel, R., Hahne, S., Merkelbach-Bruse, S., Buettner, R., Wolf, J. and Scheffler, M. (2022). Small-scale ROS1 aberrations: Functional impact and therapeutic potential. Ann. Oncol., 33 (8). S. S1386 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041

Holzem, A., Nogova, L., Ihle, M. A., Woempner, C., Bitter, E., Michels, S., Fischer, R. N., Kron, A., Gerigk, U., Kern, J., Kaminsky, B., Randerath, W. J., Lorenz, J., Kambartel, K., Merkelbach-Bruse, S., Buttner, R., Scheffler, M. and Wolf, J. (2018). Co-occurrence of targetable aberrations in non-small cell lung cancer patients harboring MAP2K1 mutations. Oncol. Res. Treat., 41. S. 250 - 251. BASEL: KARGER. ISSN 2296-5262

Koleczko, S., Schaepers, C., Scheffler, M., Ihle, M., Kostenko, A., Michels, S., Fischer, R., Nogova, L., Brandes, V., Abdulla, D., Ueckeroth, F., Thurat, M., Frank, R., Eisert, A., Bitter, E., Woempner, C., Gogl, L., Merkelbach-Bruse, S., Buettner, R. and Wolf, J. (2016). A comprehensive analysis of potentially targetable genetic aberrations and clinical findings in 821 patients with squamous-cell NSCLC - a comparison of NGM and TCGA LUSC data. Ann. Oncol., 27. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041

Nogova, L., Malchers, F., Bitter, E., Michels, S., Fischer, R., Scheffler, M., Gardizi, M., Brandes, V., Scheel, A. H., Kambartel, K., Krueger, S. ORCID: 0000-0002-1658-5993, Serke, M., Isaacs, R., Porter, D., Buettner, R., Thomas, R. K. and Wolf, J. (2017). Fibroblast kinase 1-3 inhibitor BGJ398 in patients with FGFR1 amplified squamous non-small cell lung cancer treated in a phase I study: evaluation of tumor tissue and response at a single center. Oncol. Res. Treat., 40. S. 137 - 139. BASEL: KARGER. ISSN 2296-5262